Vulcan Value Partners LLC Increases Stake in IQVIA Holdings Inc. $IQV

Vulcan Value Partners LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 680,933 shares of the medical research company’s stock after purchasing an additional 12,177 shares during the period. IQVIA makes up about 2.4% of Vulcan Value Partners LLC’s portfolio, making the stock its 13th biggest position. Vulcan Value Partners LLC owned approximately 0.40% of IQVIA worth $129,914,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc increased its position in shares of IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after acquiring an additional 53 shares during the period. CVA Family Office LLC grew its stake in IQVIA by 11.6% during the 3rd quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 68 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of IQVIA by 11.0% in the third quarter. UMB Bank n.a. now owns 749 shares of the medical research company’s stock valued at $142,000 after purchasing an additional 74 shares during the period. E Fund Management Co. Ltd. lifted its holdings in shares of IQVIA by 3.7% during the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock worth $331,000 after purchasing an additional 74 shares during the period. Finally, Hartford Investment Management Co. boosted its position in IQVIA by 0.8% in the third quarter. Hartford Investment Management Co. now owns 9,964 shares of the medical research company’s stock valued at $1,893,000 after buying an additional 77 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 2.2%

IQV opened at $165.63 on Monday. The company has a fifty day moving average of $217.61 and a two-hundred day moving average of $208.66. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The stock has a market capitalization of $28.11 billion, a price-to-earnings ratio of 21.07, a PEG ratio of 1.60 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on IQV. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research note on Friday, February 6th. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Morgan Stanley set a $240.00 price target on IQVIA in a research report on Wednesday, February 11th. Finally, Citigroup decreased their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $235.20.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.